Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
PROJECT SUMMARY Influenza virus is a significant pathogen in solid organ transplant (SOT) recipients, including lung transplant recipients. Compared to other solid organs, patients with lung transplants experience more severe influenza disease, including respiratory failure, acute cellular rejection, antibody-mediated rejection, and chronic lung allograft dysfunction. Inactivated influenza vaccines (IIVs) are recommended for all immunocompromised individuals six months and older to mitigate severe influenza illness. However, lung transplant recipients respond poorly to standard dose (SD)-IIV due to the high levels of maintenance immunosuppression required to prevent allograft rejection. Recent studies have investigated two strategies to overcome attenuated immune responses to SD-IIV in SOT recipients: administration of one high-dose (HD)-IIV or two doses of SD-IIV in the same influenza season. However, these studies were conducted during the late post-transplant period (e.g., >1 year) and lacked crucial information from the early post-transplant phase when SOT patients are most vulnerable to influenza. Additionally, prior studies had limited representation of lung transplant recipients, a population at greater risk for influenza-related morbidity and mortality compared to other SOT recipients. We are conducting an NIH-sponsored clinical trial comparing two doses of HD-IIV to two doses of SD-IIV administered within the same season to lung transplant recipients 1-35 months post-transplant (DMID protocol number 22-0014). However, our current study does not address whether two doses of IIV are necessary for the subsequent influenza season and, relatedly, the required dose level (standard vs. high) to confer safe and sufficient protection in the subsequent season. The proposed research will compare the immunogenicity and safety of two doses of HD-IIV to two doses of SD-IIV in lung transplant recipients over two consecutive influenza seasons, elucidate cellular immune phenotypes and responses to vaccination, and define cellular immune predictors and correlates of influenza vaccine antibody responses in repeatedly vaccinated lung transplant recipients. The central immunogenicity hypothesis of our proposal is that within each vaccine group, the hemagglutination inhibition (HAI) geometric mean titer (GMT) following one vaccine dose in the repeater year will exceed the HAI GMT following two doses in the first year. To test this hypothesis and address critical knowledge gaps outlined above, lung transplant patients at Vanderbilt University Medical Center enrolled in DMID protocol number 22-0014 during the 2024-2025 and 2025-2026 influenza seasons will be enrolled the following season (2025-2026 and 2026-2027, respectively) in the proposed study and receive either two doses of HD-IIV or two doses of SD-IIV by replicating their respective first-season dose assignments. Results of this study will provide comprehensive insights into humoral and cellular immune responses in adult lung transplant recipients and guide long-term vaccine recommendations. Moreover, our findings will inform optimal vaccine strategies in other SOT populations.
Grant Summary
Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $888K for university, nonprofit, healthcare org. Applications are due 2031-03-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $888K
2031-03-31
- 1Confirm your organization is eligible for Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients: Frequently Asked Questions
Who is eligible for the Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients?
Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients provide?
Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients provides up to $888K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients deadline?
Applications for Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients are due 2031-03-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients?
To apply for Immunogenicity and Safety of High-Dose vs. Standard-Dose Influenza Vaccines Administered Over Consecutive Seasons to Lung Transplant Recipients, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.